Moving Forward with Master Validation Plan
Tasco Holdings International (OTCBB: THII) Will Utilize Liquid Nitrogen Vapor Tanks for Storage Testing
Tasco Holding International has received and installed a CBS V5000 Isothermal liquid nitrogen vapor storage tank and a K Series cryo-storage tank for stem cell storage.
As Bio-Matrix builds its state-of-the-art stem cell research and storage facility in San Diego, California, the Company will utilize the new CBS V5000 cryo-tank as the flagship for cellular storage at the facility. This new technology will validate central liquid nitrogen supply that feeds all units housed at the Bio-Matrix facility.
“An investment in this new, V-5000 Isothermal Liquid Nitrogen tank and K Series tank allows Bio-Matrix to enter into system testing, which will lead to accepting stem cell storage. This is an important step toward establishing the Company’s Good Manufacturing Practices (cGMPs) and Good Tissue Practices (cGTP) quality systems which is an important part of our facility master validation plan that will enhance our ability to provide superior stem cell storage over the long term,” said Bio-Matrix Scientific Group Managing Director and COO Brian Pockett.
A Company spokesperson said the Company expects to open the facility for business by the end of September 2006, anticipating revenue in the 4th Quarter of 2006.
Bio-Matrix’s new 15,000-sq.-ft., state-of-the-art facility, located in the heart of San Diego, will house the nation’s premiere center for stem cell storage, including:
�
-
Four research laboratories;
-
Aseptic cellular/tissue processing rooms; and
- Bio-Matrix’s secure Cryogenic Stem Cell Bank;
-
Hematology, microbiology and flow cytometry laboratories.
Stem Cell Research May Have the Ability to Change the Way Disease is Treated
Many medical researchers are of the opinion that stem cell research has the ability to change the underlying way we treat many human diseases. Stem cell therapies typically repair specific tissues or are used as a way to grow organs. However, it is also believed that this field of science is still in its infancy, and the possibility of these types of applications is still far away. Despite the fact that the market potential for stem cell therapies is very large, the industry is still in the nascent stage and expected to grow significantly going forward.
Storage of Adult Stem Cells Important Element of Industry
Reproductive cells and blood cells have been successfully stored at ultra low temperatures to suspend cellular metabolism for more than 15 years, and then unfrozen and transplanted into the patient’s body when required.
�
Stem Cell Banks
Stem cell banking facilities have been available in the U.S. for fifteen years and there are currently 23 cord blood banks operating in the country. Three companies – Cryo-Cell International, Inc., Cord Blood Registry and Viacell, Inc. – collectively own 80% of the market share. However, compliance with the Food and Drug Administrations’ operation requirements provide a major entry barrier into the stem cell banking industry, as there are significant costs associated with compliance.
Today’s stem cell therapies depend on cells donated by other people, thereby raising the chances of the patient’s immune system rejecting the donor cell. Current research may make it possible for people to use their own stem cells to regenerate tissue. Scientists believe that they will soon be able to manipulate stem cells taken from adults to create new tissue in the lab and re-transplant the same in the patient’s body, where it can work to restore an impaired function.Apart from that, therapeutic cloning may also help in the creation of embryonic stem cells, genetically similar to the patient. Another possibility is to develop a drug that would direct a stem cell to restore the lost function in a patient’s body. This would also do away with the invasive surgical procedures required to harvest and transplant stem cells.
Some examples of treatments include replacing the dopamine-producing cells in the brains of people with Parkinson’s, developing insulin producing cells for Type I Diabetes, and repairing damaged heart muscles from heart attack with cardiac muscle cells.
Sources:
OTC Financial Network
Peter Clark
Tel: 781-444-6100, Ext. 629
Fax: 781-444-6101
peter@otcfn.com
www.otcfn.com/thii
� and Tasco Holdings International
Bio-Matrix Scientific Group Inc
David Koos, 619-398-3517
and Beacon Equity Research/THII
About Tasco Holdings Inc. Tasco Holdings Inc. recently purchased Bio-Matrix Scientific Group Inc. (www.BMXGonline.com), a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market. The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego, California, to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.
Safe Harbor Provision: This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include “…will also allow us to expand the market for the Ginger Kelly Collection beyond North America, thereby greatly increasing shareholder value” and are based on the Company’s current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. Risk factors include, lack of inventory financing, foreign currency fluctuations, availability of product, uncertainty concerning market acceptance of its products, competition and other risk factors as outlined in the Company’s SEC filings. Forward Looking Statement: The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements to the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward- looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development and acceptance, the impact of competitive services and pricing, or general economic risks and uncertainties.
Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4258. Web: StockGuru.com. Email: Publisher@Stockguru.com.
Disclosure: Pentony Enterprises LLC was compensated $10,000.00 for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.